NR4A3 and extraskeletal myxoid chondrosarcoma: Genetically, gene fusions involving nuclear receptor subfamily 4 group A member 3 (NR4A3) and resulting in NR4A3 constitutive expression are exclusive to EMC and considered a hallmark of the disease (Stacchiotti et al. 2020).